About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

At the moment the company generates 92M USD in revenues.

On its last earning announcement, the company reported a loss of -6.97$ per share.

The book value per share is 16.10$

Alnylam Pharmaceuticals, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
92M - -742M -807.90% -692M -6.97 - - 99M 16.10 -515M -110M -625M